Chemoprevention of prostate cancer. Focus on key opportunities and clinical trials

Urol Clin North Am. 2003 May;30(2):227-37. doi: 10.1016/s0094-0143(02)00178-7.

Abstract

By 2004-2005, the final results of the Prostate Cancer Prevention Trial should be available. Within several years thereafter, results of the SELECT should be available. The growing list of potential agents for prostate cancer prevention continues to grow and includes COX-2 inhibitors, vitamin D, dietary interventions (soy, isoflavenoids, low-fat diet), and many others. As prospective trials are completed and molecular genetic correlations are developed, it is almost certain that specific recommendations, tailored to the individual patient, will be developed. Ultimately, through these efforts, it can be anticipated that the primary focus for control of prostate cancer will shift from early detection and treatment to prevention.

Publication types

  • Review

MeSH terms

  • Antioxidants / therapeutic use
  • Chemoprevention
  • Clinical Trials as Topic
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / therapeutic use
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Male
  • Membrane Proteins
  • Prostaglandin-Endoperoxide Synthases
  • Prostatic Neoplasms / epidemiology
  • Prostatic Neoplasms / prevention & control*
  • Risk Assessment
  • Risk Factors
  • Selenium / therapeutic use
  • Vitamin E / therapeutic use

Substances

  • Antioxidants
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Membrane Proteins
  • Vitamin E
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Selenium